Does Fallon Community Health Plan (FCHP) Cover Dupixent?

Understanding Dupixent and Why Coverage Matters

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, two cytokines that drive type 2 inflammation across multiple organ systems. The FDA first approved dupilumab for moderate-to-severe atopic dermatitis in adults in March 2017, and indications have since expanded to include asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, and COPD 1.

At a list price exceeding $39,000 per year, insurance coverage is not optional for most patients. A 2023 analysis published in JAMA Dermatology found that prior authorization denials for biologics in atopic dermatitis delayed treatment initiation by a median of 34 days, with 18% of patients abandoning therapy entirely after a first denial 2. Understanding exactly what Fallon Health requires before you file can save weeks of back-and-forth.

Fallon Community Health Plan, which rebranded to Fallon Health in 2014 but is still widely searched under its original name, serves members primarily in Massachusetts. It offers commercial HMO, PPO, Medicare Advantage, and MassHealth (Medicaid) managed care products. Each product line carries its own formulary, but the prior authorization criteria for Dupixent are broadly consistent across tiers.

FCHP Formulary Placement and Tier Status

Dupixent sits on the specialty pharmacy tier (typically Tier 5 or Tier 6) across Fallon Health commercial and Medicare Advantage formularies. Specialty tier placement means the drug is dispensed through a designated specialty pharmacy rather than a retail location.

For most Fallon Health commercial plans, specialty tier copays range from 20% to 33% coinsurance after the deductible. On a $3,300 monthly cost, that translates to $660 to $1,089 out-of-pocket per fill before any copay assistance. Medicare Advantage members face a different structure: the 2026 Medicare Part D redesign caps annual out-of-pocket drug spending at $2,000, which substantially reduces long-term exposure for Medicare enrollees on Dupixent 3.

MassHealth (Medicaid) managed care plans administered by Fallon Health generally cover Dupixent with $0 to minimal copays, though prior authorization requirements still apply. The MassHealth Drug List classifies dupilumab as requiring prior approval for all ages 4.

Fallon Health Dupixent Coverage Decision Framework:

1. Identify your plan type (Commercial HMO/PPO, Medicare Advantage, or MassHealth ACO)
2. Confirm specialty tier copay/coinsurance percentage on your Summary of Benefits
3. Check whether your plan year deductible has been met
4. Determine if manufacturer copay assistance (Dupixent MyWay) applies to your plan type (commercial only, not government programs)
5. Contact Fallon Health pharmacy services at the number on your member ID card to confirm current prior authorization criteria

Prior Authorization Requirements at Fallon Health

Every Fallon Health plan requires prior authorization before dispensing Dupixent. The prescribing clinician (typically a dermatologist, allergist, pulmonologist, or gastroenterologist) must submit documentation proving the member meets specific clinical criteria.

For atopic dermatitis, Fallon Health's medical policy generally mirrors criteria used by most Massachusetts commercial payers. Typical requirements include: a confirmed diagnosis of moderate-to-severe atopic dermatitis (Investigator Global Assessment score of 3 or 4, or body surface area involvement of 10% or greater); documented failure, intolerance, or contraindication to at least one conventional systemic therapy such as methotrexate, cyclosporine, mycophenolate, or azathioprine; and inadequate response to topical corticosteroids and/or topical calcineurin inhibitors 5.

For asthma, the requirements align with GINA Step 4/5 criteria: the member must have moderate-to-severe asthma with an eosinophilic phenotype (blood eosinophils of 150 cells/mcL or higher) or oral corticosteroid-dependent asthma, with documented inadequate control despite medium-to-high-dose inhaled corticosteroid plus a second controller 6.

For CRSwNP, documentation of bilateral nasal polyps on endoscopy and inadequate response to intranasal corticosteroids is standard. The SINUS-24 trial (N=276) demonstrated that dupilumab reduced nasal polyp score by 1.89 points vs. 0.17 for placebo at 24 weeks, a result that supports payer coverage but still requires prior authorization documentation 7.

Dr. Lisa Beck, Professor of Dermatology at the University of Rochester Medical Center and a principal investigator on the LIBERTY AD trials, has stated: "The prior authorization process for dupilumab remains one of the most significant barriers to care for patients with moderate-to-severe atopic dermatitis. Documentation of disease severity using validated scoring tools like EASI or IGA is not just good clinical practice; it is the language payers require" 8.

Step Therapy: What You Must Try First

Step therapy (sometimes called "fail-first") is a cost-management tool that requires patients to try less expensive treatments before a payer will approve a higher-cost biologic. Fallon Health applies step therapy to Dupixent on most commercial plans.

For atopic dermatitis, the typical step therapy sequence at Fallon Health requires:

Step 1: Adequate trial of topical corticosteroids (at least medium potency) and/or topical calcineurin inhibitors (tacrolimus or pimecrolimus) for a minimum of 4 to 8 weeks.

Step 2: Trial and documented failure of at least one conventional systemic immunosuppressant. Methotrexate and cyclosporine are the most commonly required, though some plans accept mycophenolate or azathioprine. A "failure" is typically defined as lack of adequate response after 12 or more weeks at therapeutic doses, or discontinuation due to adverse effects.

Step 3: If the member has completed steps 1 and 2 with documentation, Dupixent may be approved.

A 2022 retrospective cohort study in the Journal of the American Academy of Dermatology found that step therapy requirements for biologics in atopic dermatitis were associated with a 42% increase in emergency department visits for disease flares during the step therapy period, compared to patients with direct biologic access 9. This finding has fueled advocacy for step therapy reform in Massachusetts, though no legislation eliminating biologic step therapy has passed as of mid-2026.

Some Fallon Health plans may also require trial of JAK inhibitors (such as abrocitinib or upadacitinib) before approving Dupixent, or vice versa. The American Academy of Dermatology guidelines do not mandate a specific sequence between JAK inhibitors and biologics, noting that the choice should be individualized based on patient comorbidities, risk tolerance, and preference 10.

How to File a Prior Authorization Request

The prior authorization process at Fallon Health follows a standard workflow, but knowing the details can prevent avoidable delays.

Who submits: Your prescribing physician's office submits the prior authorization, not the patient. The request goes to Fallon Health's pharmacy benefit manager (PBM). Fallon Health has used different PBM partners across plan lines, so the exact submission portal may vary.

What to include: The strongest prior authorization submissions package four elements together. First, clinical notes documenting diagnosis, severity scores (EASI, IGA, BSA for atopic dermatitis; FEV1, eosinophil count for asthma), and treatment history. Second, prescription details including dose, frequency, and duration. Third, a letter of medical necessity from the prescriber explaining why Dupixent is required and why alternatives are insufficient. Fourth, pharmacy information confirming the dispensing specialty pharmacy is in Fallon Health's network.

Turnaround times: Standard prior authorization decisions take 5 to 15 business days. Urgent or expedited requests, appropriate when a delay could cause serious harm, must be decided within 24 to 72 hours per Massachusetts Division of Insurance regulations. If Fallon Health fails to respond within the required timeframe, the request is deemed approved by default under Massachusetts law (M.G.L. c. 176O, § 6).

Approval duration: Initial approvals typically cover 6 to 12 months. Reauthorization requires updated clinical documentation showing continued medical necessity and treatment response.

What to Do If Coverage Is Denied

A denial is not the end. Fallon Health members have multiple layers of appeal, and denial overturn rates for biologics are meaningful.

Internal appeal: You have 60 days from the date of the denial letter to file an internal appeal. Include updated clinical documentation, any new lab results (especially eosinophil counts or IgE levels for asthma indications), photographs of skin disease if applicable, and a detailed letter from your physician. The internal appeal is reviewed by a physician who was not involved in the original denial decision.

External review: If the internal appeal is denied, Massachusetts law entitles you to an independent external review through the Office of Patient Protection (OPP). The external reviewer is a board-certified physician in the relevant specialty. A 2021 analysis of Massachusetts OPP data showed that external reviews overturned biologic denials in approximately 52% of cases 11.

Peer-to-peer review: Before or during the appeal process, your prescriber can request a peer-to-peer conversation with Fallon Health's medical director. This direct clinician-to-clinician discussion sometimes resolves authorization issues faster than the written appeal process.

Dr. Jonathan Silverberg, Director of Clinical Research in the Department of Dermatology at George Washington University, has noted: "Payers are increasingly recognizing the long-term cost-effectiveness of dupilumab, particularly when you factor in reduced ED visits, fewer hospitalizations for skin infections, and decreased need for systemic corticosteroids. The LIBERTY AD CHRONOS trial demonstrated sustained efficacy through 52 weeks, which is the kind of durability data that supports long-term coverage" 12.

Reducing Your Out-of-Pocket Cost

Even with Fallon Health coverage, the specialty tier coinsurance on Dupixent can be substantial. Several strategies can reduce what you actually pay.

Dupixent MyWay copay card: Sanofi's manufacturer copay assistance program covers up to $13,000 per year in out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 per fill. The program is not available to members on government insurance (Medicare, Medicaid, Tricare, VA). Enrollment is available at the Dupixent MyWay website or by calling 1-844-DUPIXENT.

Fallon Health specialty pharmacy coordination: Fallon Health contracts with specific specialty pharmacies for Dupixent dispensing. Using an out-of-network specialty pharmacy will result in higher costs or outright denial. Confirm your plan's designated specialty pharmacy before the first fill.

Accumulator adjuster programs: Some Fallon Health plan designs use accumulator adjustment programs that prevent manufacturer copay assistance from counting toward the member's annual deductible or out-of-pocket maximum. If your plan uses an accumulator, the Dupixent MyWay copay card will cover your coinsurance for the first portion of the year, but once the card's annual benefit is exhausted, you will be responsible for the full coinsurance until you reach your plan's out-of-pocket maximum. Ask Fallon Health's member services whether your plan uses an accumulator or a maximizer program.

Patient assistance for uninsured or underinsured: Patients without insurance or with inadequate coverage may qualify for Sanofi's patient assistance program, which provides Dupixent at no cost to eligible individuals with household incomes at or below 400% of the federal poverty level.

Dupixent Coverage by Indication: What the Trials Show

Fallon Health's coverage criteria are informed by clinical trial data. The strength of evidence varies by indication, which can influence how readily prior authorization is approved.

Atopic dermatitis has the deepest evidence base. The LIBERTY AD SOLO 1 trial (N=671) demonstrated that 38% of patients receiving dupilumab 300 mg every two weeks achieved clear or almost-clear skin (IGA 0/1) at 16 weeks, compared to 10% on placebo 13. The LIBERTY AD CHRONOS trial (N=740) confirmed sustained efficacy at 52 weeks with concomitant topical corticosteroids 12.

Moderate-to-severe asthma approval relies primarily on the LIBERTY ASTHMA QUEST trial (N=1,902), which showed a 47.7% reduction in severe exacerbation rate with dupilumab in patients with baseline eosinophils of 300 cells/mcL or higher 14. This trial enrolled a broad population, which strengthens payer confidence in the indication.

Eosinophilic esophagitis received FDA approval in 2022 based on Part A of the three-part study (N=81), in which 60% of patients on dupilumab achieved histologic remission (peak eosinophil count of 6 or fewer per high-power field) at 24 weeks, compared to 5% on placebo 15. Because EoE is a newer indication, some payer policies lag behind the FDA label. If Fallon Health's current formulary criteria do not list EoE, your physician can request an exception review citing the FDA approval and trial data.

Prurigo nodularis approval came from the LIBERTY-PN PRIME and PRIME2 trials, which showed 60% of dupilumab-treated patients achieved a 4-point or greater reduction in worst-itch numerical rating scale score at 24 weeks 16. This is one of the few effective treatments for a condition that has historically had no FDA-approved therapies.

Special Considerations for Massachusetts Members

Massachusetts has several state-level protections that affect how Fallon Health administers Dupixent coverage.

The state's Mental Health Parity and Addiction Equity Act, combined with general medical necessity protections under M.G.L. c. 176O, requires that coverage determinations for chronic disease treatments be based on clinical evidence rather than cost alone. If Dupixent is the only FDA-approved treatment for your specific condition (as is the case for prurigo nodularis, where alternatives are limited), the argument for medical necessity is particularly strong.

Massachusetts also requires commercial insurers to provide continuity of coverage when members switch plans during open enrollment. If you were receiving Dupixent under a different insurer and transition to Fallon Health, you may be entitled to continued coverage during a transition period while the new prior authorization is processed.

For MassHealth members enrolled in Fallon Health's ACO plan, Dupixent access follows MassHealth's prior authorization criteria, which are published in the MassHealth Drug List and associated clinical criteria documents 4. MassHealth criteria may differ from commercial criteria, particularly regarding step therapy requirements.

Pediatric members (ages 6 months and older for atopic dermatitis, 6 years and older for asthma) may face additional documentation requirements, including weight-based dosing verification and confirmation of diagnosis by a pediatric subspecialist.